M. Guttman And NotAllemagne
List of bibliographic references
Number of relevant bibliographic references: 32.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 002185 | J. E. Tobin ; J. C. Latourelle ; M. F. Lew ; C. Klein ; O. Suchowersky ; H. A. Shill ; L. I. Golbe ; M. H. Mark ; J. H. Growdon ; G. F. Wooten ; B. A. Racette ; J. S. Perlmutter ; R. Watts ; M. Guttman ; K. B. Baker ; S. Goldwurm ; G. Pezzoli ; C. Singer ; M. H. Saint-Hilaire ; A. E. Hendricks ; S. Williamson ; M. W. Nagle ; J. B. Wilk ; T. Massood ; J. M. Laramie ; A. L. Destefano ; I. Litvan ; G. Nicholson ; A. Corbett ; S. Isaacson ; D. J. Burn ; P. F. Chinnery ; P. P. Pramstaller ; S. Sherman ; J. Al-Hinti ; E. Drasby ; M. Nance ; A. T. Moller ; K. Ostergaard ; R. Roxburgh ; B. Snow ; J. T. Slevin ; F. Cambi ; J. F. Gusella ; R. H. Myers | Haplotypes and gene expression implicate the MAPT region for Parkinson disease |
| 002360 | Peter A. Lewitt [États-Unis] ; M. Guttman [Canada] ; James W. Tetrud [États-Unis] ; Paul J. Tuite [États-Unis] ; Akihisa Mori [Japon] ; Philip Chaikin [États-Unis] ; Neil M. Sussman [États-Unis] | Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005) |
| 002418 | Peter A. Lewitt [États-Unis] ; M. Guttman [Canada] ; James W. Tetrud [États-Unis] ; Paul J. Tuite [États-Unis] ; Akihisa Mori [Japon] ; Philip Chaikin [États-Unis] ; Neil M. Sussman [États-Unis] | Adenosine A2A Receptor Antagonist Istradefylline (KW-6002) Reduces "Off' Time in Parkinson's Disease : A Double-Blind, Randomized, Multicenter Clinical Trial (6002-US-005) |
| 002606 | M. Guttman [Canada] ; I. Boileau [Canada] ; J. Warsh [Canada] ; J. A. Saint-Cyr [Canada] ; N. Ginovart [Canada] ; T. Mccluskey [Canada] ; S. Houle [Canada] ; A. Wilson [Canada] ; E. Mundo [Italie] ; P. Rusjan [Canada] ; J. Meyer [Canada] ; S. J. Kish [Canada] | Brain serotonin transporter binding in non‐depressed patients with Parkinson's disease |
| 002D59 | D. Coyle [Canada] ; M. Barbeau ; M. Guttman ; J-F Baladi | The economic evaluation of pharmacotherapies for Parkinson's disease. |
| 003062 | M. Guttman [Canada] ; P. M. Slaughter [Canada] ; M.-E. Theriault [Canada] ; D. P. Deboer [Canada] ; C. D. Naylor [Canada] | Parkinsonism in Ontario: Physician utilization |
| 003092 | C. E. Clarke [Royaume-Uni] ; M. Guttman [Canada] | Dopamine agonist monotherapy in Parkinson's disease |
| 003106 | M. Guttman [Canada] ; J. Jaskolka | The use of pramipexole in Parkinson's disease: are its actions D(3) mediated? |
| 003111 | M. Guttman [Canada] ; P M Slaughter ; M E Theriault ; D P Deboer ; C D Naylor | Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study. |
| 003160 | M. Guttman [Canada] ; J. Jaskolka [Canada] | The use of pramipexole in Parkinson's disease: are its actions D3 mediated? |
| 003308 | M. Guttman [Canada] ; D. Stewart [Canada] ; D. Hussey [Canada] ; A. Wilson [Canada] ; S. Houle [Canada] ; S. Kish [Canada] | Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD |
| 003808 | M. Guttman [Canada] ; O. Suchowersky [Canada] | Parkinson's disease management : Towards a new paradigm |
| 003A60 | M. Guttman [Canada] ; J. Burkholder ; S J Kish ; D. Hussey ; A. Wilson ; J. Dasilva ; S. Houle | [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. |
| 003C31 | M. Guttman [Canada] ; J. Burkholder [États-Unis] ; S. J. Kish [Canada] ; D. Hussey [États-Unis] ; A. Wilson [États-Unis] ; J. Dasilva [États-Unis] ; S. Houle [États-Unis] | [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease : Implications for the symptomatic threshold |
| 003C66 | M. Guttman [Canada] | Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease |
| 003F01 | J. M. Wilson [Canada] ; A. I. Levey [États-Unis] ; A. Rajput [Canada] ; L. Ang [Canada] ; M. Guttman [Canada] ; K. Shannak [Canada] ; H. B. Niznik [Canada] ; O. Hornykiewicz [Canada, Autriche] ; C. Pifl [Autriche] ; S. J. Kish [Canada] | Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease |
| 004086 | H. Kuwabara [Canada] ; P. Cumming ; Y. Yasuhara ; G. C. Leger ; M. Guttman ; M. Diksic ; A. C. Evans ; A. Gjedde | Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease |
| 004318 | H. Hoshi [Canada] ; H. Kuwabara ; G. Léger ; P. Cumming ; M. Guttman ; A. Gjedde | 6-[18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods. |
| 004430 | M. Guttman [Canada] ; G. Léger [Canada] ; A. Reches [Israël] ; A. Evans [Canada] ; H. Kuwabara [Canada] ; J. M. Cedarbaum [États-Unis] ; J. M. Gjedde [Canada] | Administration of the new COMT inhibitor OR‐611 increases striatal uptake of fluorodopa |
| 004435 | A. Gjedde [Canada] ; G. C. Leger ; P. Cumming ; Y. Yasuhara ; A. C. Evans ; M. Guttman ; H. Kuwabara | Striatal L-DOPA decarboxylase activity in Parkinson's disease in vivo : implications for the regulation of dopamine synthesis |
| 004465 | H. Hoshi [Canada] ; H. Kuwabara ; G. Leger ; P. Cumming ; M. Guttman ; A. Gjedde | 6-[18F]fluoro-L-DOPA metabolism in living human brain : a comparison of six analytical methods |
| 004650 | M. Guttman [Canada] | Dopamine receptors in Parkinson's disease |
| 004657 | R. F. Peppard [Canada] ; R. Wayne Martin [Canada] ; G. D. Carr ; E. Grochowski ; M. Schulzer [Canada] ; M. Guttman [Canada] ; P. L. Mcgeer ; A. G. Phillips ; J. K. C. Tsui [Canada] ; D. B. Calne [Canada] | Cerebral glucose metabolism in Parkinson's disease with and without dementia |
| 004988 | B. J. Snow ; R. F. Peppard ; M. Guttman ; J. Okada ; W. Martin ; J. Steele ; A. Eisen ; G. Carr ; B. Schoenberg ; D. Calne | Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in lytico-bodig : the amyotrophic lateral sclerosis-Parkinsonism-dementia complex of guam |
| 004993 | M. Guttman ; H. C. Fibiger ; A. Jakubovic ; D. B. Calne | Intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration: biochemical and behavioral observations in a primate model of hemiparkinsonism |
| 004B25 | VOON WEE YONG ; M. Guttman ; S. U. Kim ; D. B. Calne ; I. Turnbull ; K. Watabe ; R. W. W. Tomlinson | Transplantation of human sympathetic neurons and adrenal chromaffin cells into parkinsonian monkeys: no reversal of clinical symptoms |
| 004B32 | M. Guttman ; R. S. Burns ; W. R. W. Martin ; R. F. Peppard ; M. J. Adam ; T. J. Ruth ; G. Allen ; R. A. Parker ; N. B. Tulipan ; D. B. Calne | PET studies of Parkinsonian patients treated with autologous adrenal implants |
| 004C39 | M. Guttman [Canada] ; V. W. Yong [Canada] ; S. U. Kim [Canada] ; D. B. Calne [Canada] ; W. R. W. Martin [Canada] ; M. J. Adam [Canada] ; T. J. Ruth [Canada] | Asymptomatic striatal dopamine depletion: PET scans in unilateral MPTP monkeys |
| 004C64 | E. C. Wolters ; J. C. Kebabian ; M. Guttman ; E. Mak ; B. D. Pate ; D. B. Calne | A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys |
| 004F05 | M. Guttman ; P. Seeman ; G. P. Reynolds ; P. Riederer ; K. Jellinger ; W. W. Tourtellotte | Dopamine D2 receptor density remains constant in treated Parkinson's disease |
| 004F06 | M. Guttman ; P. Seeman ; G. P. Reynolds ; P. Riederer ; K. Jellinger ; W. W. Tourtellotte | Dopamine D2 receptor density remains constant in treated Parkinson's disease |
| 004F17 | M. Guttman [Canada] ; P. Seeman [Canada] | L-DOPA reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum |
| This area was generated with Dilib version V0.6.29. |  |